Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2006 |
| Outros Autores: | , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| DOI: | 10.1111/j.1478-3231.2006.01345.x |
| Texto Completo: | https://arca.fiocruz.br/handle/icict/7858 |
Resumo: | Faculty of Medicine University Hospital of Bahia. Gastro-Hepatology Unit. Salvador, BA, Brasil |
| id |
CRUZ_17f3c6227f559a67c848ce63d2b42f02 |
|---|---|
| oai_identifier_str |
oai:arca.fiocruz.br:icict/7858 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Paraná, RaymundoSchinoni, Maria IsabelFreitas, Luiz Antonio Rodrigues deCodes, LianaCruz, MarlaAndrade, Zilton de AraújoTrépo, Christian2014-06-30T18:39:42Z2014-06-30T18:39:42Z2006PARANÁ, R. et al. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver International, v. 26, p. 1148-1154, 2006.1478-3223https://arca.fiocruz.br/handle/icict/785810.1111/j.1478-3231.2006.01345.xengBlackwell MunksgaardAnti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis Cinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFaculty of Medicine University Hospital of Bahia. Gastro-Hepatology Unit. Salvador, BA, BrasilFederal University of Bahia. Post Graduated Program on Medicine and Health Faculty of Medicine. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, BrasilFederal University of Bahia. Post Graduated Program on Medicine and Health Faculty of Medicine. Salvador, BA, BrasilLEME Laboratory. Salvador, BA, BrasilFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, BrasilINSERM_U. University Claude Bernard. Lyon, FranceBackground/Aim: Pegylated interferon (Peg-IFN) plus ribavirin is the standard therapy for hepatitis C. Peg-IFN has several antiviral mechanisms, but its role in hepatitis C treatment seems to be related to its immunomodulatory effect. Ribavirin, an antiviral agent, potentiates IFN activity when added to it. Both drugs are associated with adverse reactions of different magnitudes. Autoimmune phenomena have been reported with this treatment. In this paper, we describe cases of ALT/GGT flares during Peg- IFN plus ribavirin treatment, which related to the appearance of anti-Golgi antibody and disease progress. Methods: We investigated three patients with hepatitis C and severe ALT/GGT flares during Peg-IFN and ribavirin treatment coinciding with anti-Golgi complex antibody as the only marker of autoimmunity. We then reviewed the medical files and tested anti-Golgi antibody in stored sera from 25 patients treated with conventional IFN and in 14 patients treated with Peg-IFN. Results: The three patients were male, over 45 years of age; all were relapsers and non-responders. Anti-Golgi antibody was positive during treatment coinciding with ALT/GGT flares but with hepatitis C virus (HCV)-RNA negativity, disappearing after stopping treatment, with normalization of ALT/AST levels. One patient had progression of fibrosis from F2 to F3 despite negativity of HCV-RNA. In the last group, only two patients treated with Peg-IFN experienced ALT/GGT flares but without anti-Golgi antibody Conclusions: The presence of anti- Golgi complex antibody could be a marker of a temporary autoimmune phenomenon and progressive disease.Antivirais/efeitos adversosAutoanticorpos/sangueComplexo de Golgi/imunologiaHepatite C/sangueHepatite C/quimioterapiaInterferon-alfa/efeitos adversosPolietilenoglicóis/efeitos adversosRibavirina/efeitos adversosAlanina Transaminase/sangueAntivirais/uso terapêuticoProgressão da DoençaQuimioterapia CombinadaHepacivirus/genéticaInterferon-alfa/uso terapêuticoHumanosFígado/patologiaCirrose Hepática/patologiaPolietilenoglicóis/uso terapêuticoMasculinoMeia-IdadeProteínas RecombinantesRibavirina/uso terapêuticoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALPArana R Anti-golgi....pdfPArana R Anti-golgi....pdfapplication/pdf597871https://arca.fiocruz.br/bitstreams/efe7338f-e2ba-49a9-86a9-1ebefd219bfc/downloadcaa0974b7b405828343650aa19017da3MD51trueAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81914https://arca.fiocruz.br/bitstreams/30e8dbe5-35b3-4c1a-aa2f-8e90ec5f5e57/download7d48279ffeed55da8dfe2f8e81f3b81fMD52falseAnonymousREADTEXTPArana R Anti-golgi....pdf.txtPArana R Anti-golgi....pdf.txtExtracted texttext/plain25897https://arca.fiocruz.br/bitstreams/e24d1540-02d9-418e-ad22-b9b0534b6cd4/download771fa2a068b1125bf61ec3866e51f1e8MD55falseAnonymousREADTHUMBNAILPArana R Anti-golgi....pdf.jpgPArana R Anti-golgi....pdf.jpgGenerated Thumbnailimage/jpeg6215https://arca.fiocruz.br/bitstreams/435c7030-ece3-4f29-9e61-1f95a9d6676c/downloadf5a20b37ce866f1c702e27e8adf42dd2MD56falseAnonymousREADicict/78582025-07-30 02:07:04.26open.accessoai:arca.fiocruz.br:icict/7858https://arca.fiocruz.brRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352025-07-30T05:07:04Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)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 |
| dc.title.none.fl_str_mv |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C |
| title |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C |
| spellingShingle |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C Paraná, Raymundo Antivirais/efeitos adversos Autoanticorpos/sangue Complexo de Golgi/imunologia Hepatite C/sangue Hepatite C/quimioterapia Interferon-alfa/efeitos adversos Polietilenoglicóis/efeitos adversos Ribavirina/efeitos adversos Alanina Transaminase/sangue Antivirais/uso terapêutico Progressão da Doença Quimioterapia Combinada Hepacivirus/genética Interferon-alfa/uso terapêutico Humanos Fígado/patologia Cirrose Hepática/patologia Polietilenoglicóis/uso terapêutico Masculino Meia-Idade Proteínas Recombinantes Ribavirina/uso terapêutico |
| title_short |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C |
| title_full |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C |
| title_fullStr |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C |
| title_full_unstemmed |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C |
| title_sort |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C |
| author |
Paraná, Raymundo |
| author_facet |
Paraná, Raymundo Schinoni, Maria Isabel Freitas, Luiz Antonio Rodrigues de Codes, Liana Cruz, Marla Andrade, Zilton de Araújo Trépo, Christian |
| author_role |
author |
| author2 |
Schinoni, Maria Isabel Freitas, Luiz Antonio Rodrigues de Codes, Liana Cruz, Marla Andrade, Zilton de Araújo Trépo, Christian |
| author2_role |
author author author author author author |
| dc.contributor.author.fl_str_mv |
Paraná, Raymundo Schinoni, Maria Isabel Freitas, Luiz Antonio Rodrigues de Codes, Liana Cruz, Marla Andrade, Zilton de Araújo Trépo, Christian |
| dc.subject.decs.none.fl_str_mv |
Antivirais/efeitos adversos Autoanticorpos/sangue Complexo de Golgi/imunologia Hepatite C/sangue Hepatite C/quimioterapia Interferon-alfa/efeitos adversos Polietilenoglicóis/efeitos adversos Ribavirina/efeitos adversos Alanina Transaminase/sangue Antivirais/uso terapêutico Progressão da Doença Quimioterapia Combinada Hepacivirus/genética Interferon-alfa/uso terapêutico Humanos Fígado/patologia Cirrose Hepática/patologia Polietilenoglicóis/uso terapêutico Masculino Meia-Idade Proteínas Recombinantes Ribavirina/uso terapêutico |
| topic |
Antivirais/efeitos adversos Autoanticorpos/sangue Complexo de Golgi/imunologia Hepatite C/sangue Hepatite C/quimioterapia Interferon-alfa/efeitos adversos Polietilenoglicóis/efeitos adversos Ribavirina/efeitos adversos Alanina Transaminase/sangue Antivirais/uso terapêutico Progressão da Doença Quimioterapia Combinada Hepacivirus/genética Interferon-alfa/uso terapêutico Humanos Fígado/patologia Cirrose Hepática/patologia Polietilenoglicóis/uso terapêutico Masculino Meia-Idade Proteínas Recombinantes Ribavirina/uso terapêutico |
| description |
Faculty of Medicine University Hospital of Bahia. Gastro-Hepatology Unit. Salvador, BA, Brasil |
| publishDate |
2006 |
| dc.date.issued.fl_str_mv |
2006 |
| dc.date.accessioned.fl_str_mv |
2014-06-30T18:39:42Z |
| dc.date.available.fl_str_mv |
2014-06-30T18:39:42Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
PARANÁ, R. et al. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver International, v. 26, p. 1148-1154, 2006. |
| dc.identifier.uri.fl_str_mv |
https://arca.fiocruz.br/handle/icict/7858 |
| dc.identifier.issn.none.fl_str_mv |
1478-3223 |
| dc.identifier.doi.none.fl_str_mv |
10.1111/j.1478-3231.2006.01345.x |
| identifier_str_mv |
PARANÁ, R. et al. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver International, v. 26, p. 1148-1154, 2006. 1478-3223 10.1111/j.1478-3231.2006.01345.x |
| url |
https://arca.fiocruz.br/handle/icict/7858 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Blackwell Munksgaard |
| publisher.none.fl_str_mv |
Blackwell Munksgaard |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://arca.fiocruz.br/bitstreams/efe7338f-e2ba-49a9-86a9-1ebefd219bfc/download https://arca.fiocruz.br/bitstreams/30e8dbe5-35b3-4c1a-aa2f-8e90ec5f5e57/download https://arca.fiocruz.br/bitstreams/e24d1540-02d9-418e-ad22-b9b0534b6cd4/download https://arca.fiocruz.br/bitstreams/435c7030-ece3-4f29-9e61-1f95a9d6676c/download |
| bitstream.checksum.fl_str_mv |
caa0974b7b405828343650aa19017da3 7d48279ffeed55da8dfe2f8e81f3b81f 771fa2a068b1125bf61ec3866e51f1e8 f5a20b37ce866f1c702e27e8adf42dd2 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1839716427458674688 |